IL298667A - tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for the treatment of cutaneous lupus erythematosus - Google Patents

tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for the treatment of cutaneous lupus erythematosus

Info

Publication number
IL298667A
IL298667A IL298667A IL29866722A IL298667A IL 298667 A IL298667 A IL 298667A IL 298667 A IL298667 A IL 298667A IL 29866722 A IL29866722 A IL 29866722A IL 298667 A IL298667 A IL 298667A
Authority
IL
Israel
Prior art keywords
pharmaceutically acceptable
acceptable salt
prednisolone
inhibitor
therapeutically effective
Prior art date
Application number
IL298667A
Other languages
English (en)
Hebrew (he)
Inventor
Gary L Schieven
Shailesh Dudhgaonkar
Original Assignee
Bristol Myers Squibb Co
Gary L Schieven
Shailesh Dudhgaonkar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Gary L Schieven, Shailesh Dudhgaonkar filed Critical Bristol Myers Squibb Co
Publication of IL298667A publication Critical patent/IL298667A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL298667A 2020-06-11 2021-06-10 tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for the treatment of cutaneous lupus erythematosus IL298667A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202011024586 2020-06-11
PCT/US2021/036740 WO2021252718A1 (en) 2020-06-11 2021-06-10 Tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus

Publications (1)

Publication Number Publication Date
IL298667A true IL298667A (en) 2023-01-01

Family

ID=76959055

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298667A IL298667A (en) 2020-06-11 2021-06-10 tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for the treatment of cutaneous lupus erythematosus

Country Status (11)

Country Link
US (1) US20230310408A1 (OSRAM)
EP (1) EP4164639A1 (OSRAM)
JP (2) JP7751597B2 (OSRAM)
KR (1) KR20230023717A (OSRAM)
CN (1) CN115701995A (OSRAM)
AU (1) AU2021286582A1 (OSRAM)
BR (1) BR112022024999A2 (OSRAM)
CA (1) CA3181964A1 (OSRAM)
IL (1) IL298667A (OSRAM)
MX (1) MX2022015760A (OSRAM)
WO (1) WO2021252718A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI861488B (zh) 2021-04-16 2024-11-11 美商基利科學股份有限公司 噻吩并吡咯化合物
US12070455B2 (en) 2021-09-10 2024-08-27 Gilead Sciences, Inc. Thienopyrrole compounds
IL327216A (en) * 2023-10-02 2026-05-01 Bristol Myers Squibb Co A method for treating lupus
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
MX338980B (es) * 2010-06-16 2016-05-06 Dynavax Tech Corp Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9.
AU2013203815A1 (en) * 2010-06-16 2013-05-02 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
WO2015200094A1 (en) * 2014-06-20 2015-12-30 Baylor Research Institute Methods and compositions for systemic lupus erythematosus (sle) therapy
US10071079B2 (en) * 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Also Published As

Publication number Publication date
KR20230023717A (ko) 2023-02-17
EP4164639A1 (en) 2023-04-19
MX2022015760A (es) 2023-01-19
JP2023530264A (ja) 2023-07-14
AU2021286582A1 (en) 2023-02-09
BR112022024999A2 (pt) 2022-12-27
JP2025183420A (ja) 2025-12-16
US20230310408A1 (en) 2023-10-05
WO2021252718A1 (en) 2021-12-16
JP7751597B2 (ja) 2025-10-08
CN115701995A (zh) 2023-02-14
CA3181964A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
US20230310408A1 (en) Tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus
ES2476368T3 (es) Tratamiento de la artritis reumatoide con una combinación de laquinimod y metotrexato
EP3206682B1 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
JP7564347B2 (ja) 多発性硬化症を治療するためのｌｏｕ０６４
JP2021106625A (ja) Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法
US20230310409A1 (en) Treating rheumatoid arthritis
JP2019526644A (ja) Ｆｘｒアゴニストの組合せ
KR20070110046A (ko) 염증 및 탈수초성 질환을 치료하기 위한 화합물
JP2024525515A (ja) がんの予防用又は治療用の医薬組成物
US20100273750A1 (en) Serotonin receptor antagonists for treating arthritis
US20210236594A1 (en) Methods for improving frailty and aging
EA048070B1 (ru) Способы лечения кожной красной волчанки
JP2018516990A (ja) シスチン・グルタミン酸トランスポーター阻害剤の新規な使用の方法
WO2008090331A1 (en) Serotonin reuptake inhibitors for treating arthritis
WO2020061636A1 (en) Treatment of neuropathic pain
EP4093395B1 (en) Eletriptan hydrobromide for treatment of spinal cord injury and improvement of locomotor function
JP2026049047A (ja) 変形性膝関節症および肩関節周囲炎の疼痛改善剤
CN118019540A (zh) 用于治疗多发性硬化的lou064
US20110053840A1 (en) Allele and isotope-specific intervention on mhc class ii molecules associated with autoimmune diseases by means of peptides
WO2025075944A1 (en) A method of treating lupus
Adgey et al. ReoPro®
WO2012110946A1 (en) Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate